PhaseBio Pharmaceuticals

NasdaqGM:PHAS Stock Report

Mkt Cap: US$9.4m

PhaseBio Pharmaceuticals Future Growth

How is PhaseBio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


42.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHAS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PHAS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PHAS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PHAS's revenue (73.8% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: PHAS's revenue (73.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PHAS's Return on Equity is forecast to be high in 3 years time


Discover growth companies